TAVR – Medxy AI

Seven-Year Outcomes of TAVR vs. Surgical Aortic Valve Replacement in Low-Risk Patients: Insights from PARTNER 3

By MedXY 10/31/2025

At 7 years, transcatheter and surgical aortic valve replacement show comparable outcomes including survival, stroke, and valve durability among low-risk patients with severe aortic stenosis, affirming TAVR's long-term efficacy.

Cardiology Clinical Updates news

Rising Trends into Transcatheter Aortic Valve Reinterventions: Redo TAVR and Explant Procedures from 2012 to 2024

By MedXY 09/27/2025

This article reviews increasing volumes and incidence of transcatheter aortic valve replacement (TAVR) reinterventions, analyzing procedural trends of redo TAVR and TAVR explant over the past decade, emphasizing implications for clinical practice and future strategies.

Cardiology Specialties

Three-Year Outcomes of NOTION-2 Trial: Comparing TAVR and SAVR in Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis

By MedXY 09/06/2025

The NOTION-2 trial demonstrates comparable three-year outcomes between TAVR and SAVR in low-risk patients aged 60-75 with severe tricuspid or bicuspid aortic stenosis, with low rates of valve deterioration and re-intervention.

Cardiology Clinical Updates news Specialties

Valve Underexpansion in ACURATE neo2 TAVR: Implications for Clinical Outcomes and Future Directions

By MedXY 08/17/2025

Underexpansion of the ACURATE neo2 valve during TAVR is linked to increased risk of death, stroke, and rehospitalization at one year, suggesting that achieving optimal valve expansion may improve patient outcomes.

Cardiology news Specialties

Early TAVR Benefits in Asymptomatic Severe Aortic Stenosis: Insights from Cardiac Biomarker Analysis in the EARLY TAVR Trial

By MedXY 08/17/2025

Cardiac biomarkers NT-proBNP and hs-cTnT predict higher risk in asymptomatic severe aortic stenosis, but early TAVR benefits patients regardless of biomarker levels, with greater relative advantage seen in those with lower biomarker concentrations.